Skip to main content
SpringerLink
Log in

Treatment of Ventilator-Associated Pneumonia

  • Chapter
Ventilator-Associated Pneumonia

Part of the book series: Perspectives on Critical Care Infectious Diseases ((CCID,volume 4))

  • 177 Accesses

Abstract

Nearly two decades have past since the beginning of research on the diagnosis of ventilator-associated pneumonia (VAP). Despite significant increases in our understanding of the pathogenesis of VAP and the operating characteristics of various diagnostic methods, the primary goal of this research into diagnosis - improved treatment and prevention strategies - remains in its infancy. Rather than the well-designed, critically reviewed studies now being performed in VAP diagnosis (1,2), the majority of data regarding treatment of VAP continues to come from pharmaceutical industry sponsored trials, designed only to show equivalence to already marketed drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al: Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: A pilot study. Am.1 Respir Crit Care Med 1998; 157: 371–376.

    Article  CAS  Google Scholar 

  2. Fagon JY, Chastre J, Wolff M, et al: Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia: A randomized trial. Ann Intern Med 2000; 132: 621–630.

    PubMed  CAS  Google Scholar 

  3. Wunderink RG: Mortality and the diagnosis of ventilator-associated pneumonia: A new direction. Am J Respir Crit Care Med 1998; 157: 349–350.

    Article  PubMed  CAS  Google Scholar 

  4. Alvarez-Lerma F: Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. Intensive Care Med 1996; 22: 387–394.

    Article  PubMed  CAS  Google Scholar 

  5. Celis R, Torres A, Gatell JM, Almela M, Rodriquez-Roisin R, Agusti-Vidal A: Nosocomial pneumonia: a multivariate analysis of risk and prognosis. Chest 1988; 93: 318–324.

    Article  PubMed  CAS  Google Scholar 

  6. Kollef MH, Ward S: The influence of mini-BAL cultures on patient outcomes: Implications for the antibiotic management of ventilator-associated pneumonia. Chest 1997; (In Press)

    Google Scholar 

  7. Luna CM, Vujacich P, Niederman MS, et al: Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111: 676–685.

    Article  PubMed  CAS  Google Scholar 

  8. Rello J, Gallego M, Mariscal D, Sonora R, Valles J: The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 196–200.

    Article  PubMed  CAS  Google Scholar 

  9. Kollef MH, Sherman G, Ward S, Fraser VJ: Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462–474.

    Article  PubMed  CAS  Google Scholar 

  10. American Thoracic Society: Hospital-acquired pneumonia in adults: Diagnosis, assessment of severity, initial antimicrobial therapy, and preventative strategies: A Consensus Statement. Am J Respir Crit Care Med 1995; 153: 1711–1725.

    Google Scholar 

  11. Rello J, Sa-Borges M, Correa H, Leal S-R, Baraibar J: Variations in etiology of ventilator-associated pneumonia across four treatment sites: Implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160: 608–613.

    Article  PubMed  CAS  Google Scholar 

  12. Trouillet J-L, Chastre J, Vuagnat A, et al: Ventilator-associated pneumonia caused by potentially drug-resistant bacteria. Am J Respir Crit Care Med 1998; 157: 531–539.

    Article  PubMed  CAS  Google Scholar 

  13. Brewer S, Wunderink R, Jones C, Leeper K: Ventilator-associated pneumonia due to Pseudomonas aeruginosa. Chest 1996; 109: 1019–1029.

    Article  Google Scholar 

  14. Wunderink R, Leeper K, Jennings SG, Jones C: Effect of ATS-recommended antibiotic therapy on mortality of Pseudomonas ventilator-associated pneumonia (PsVAP). Am l Respir Crit Care Med 1998; 157: A294(Abstract)

    Google Scholar 

  15. Rahal JJ, Urban C, Horn D, et al: Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280(14): 1233–1237.(Abstract)

    Article  PubMed  CAS  Google Scholar 

  16. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ: Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119: 353–358.

    PubMed  CAS  Google Scholar 

  17. Carmeli Y, Trouillet N, Eliopoulos GM, Samore MH: Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicr Ag Chemother 1999; 43: 1379–1382.

    CAS  Google Scholar 

  18. Trouillet JL, Vuagnat A, Kassis N, et al: Predictors-of ticarcillin resistance in ventilator-associated pneumonia (VAP) caused by P. aeruginosa. Am J Respir Crit Care Med 2000; 1611: A294(Abstract)

    Google Scholar 

  19. Baker AM, Meredith JW, Haponik EF: Pneumonia in intubated trauma patients: Microbiology and outcomes. Am.l Respir Crit Care Med 1996; 153: 343–349.

    Article  CAS  Google Scholar 

  20. Bonten MJM, Bergmans DCJJ, Stobberingh EE, et al: Implementation of bronchoscopic techniques in the diagnosis of ventilator-associated pneumonia to reduce antibiotic use. Am J Respir Crit Care Med 1997; 156: 1820–1824.

    Article  PubMed  CAS  Google Scholar 

  21. Bonten MJM, Froon AHM, Gaillard CA, et al: The systemic inflammatory response in the development of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156: 1105–1113.

    Article  PubMed  CAS  Google Scholar 

  22. Baker AM, Bowton DL, Haponick EF: Decision making in nosocomial pneumonia. An analytic approach to the interpretation of quantative bronchoscopic cultures. Chest 1995; 107: 85–95.

    Article  PubMed  CAS  Google Scholar 

  23. Cobben NAM, Jacobs JA, van Dieijen-Visser MP, Mulder PGH, Wouters EFM, Drent M: Diagnostic value of BAL fluid cellular profile and enzymes in infectious pulmonary disorders. Eur Respir J 1999; 14: 496–502.

    Article  PubMed  CAS  Google Scholar 

  24. Salata RA, Lederman MM, Shlaes DM, et al: Diagnosis of nosocomial pneumonia in intubated, intensive care unit patients. Am Rev Respir Dis 1987; 135: 426–432.

    PubMed  CAS  Google Scholar 

  25. Meduri GU, Mauldin GL, Wunderink RG, et al: Causes of fever and pulmonary densities in patients with clinical manifestations of ventilator-associated pneumonia. Chest 1994; 106:221–225.

    Article  PubMed  CAS  Google Scholar 

  26. Rouby JJ, Laurent P, Gosnach M, et al: Risk factors and clinical relevance of nosocomial maxillary sinusitis in the critically ill. Am J Respir Crit Care Med 1994; 150: 776–783.

    Article  PubMed  CAS  Google Scholar 

  27. Meehan TP, Fine MJ, Krumholz HM, et al: Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080–2084.

    Article  PubMed  CAS  Google Scholar 

  28. Wunderink RG: Pharmacoeconomics of pneumonia. Am J Surg 2000; 179 (Suppl 2A): 51S–57S.

    Google Scholar 

  29. Croce MA, Fabian TC, Shaw B, et al: Analysis of charges associated with diagnosis of nosocomial pneumonia: can routine bronchoscopy be justified? J of Trauma 1994; 37: 721–727.

    Article  CAS  Google Scholar 

  30. Fagon J-Y, Chastre J, Domart Y, Trouillet.J-L, Gibert C: Mortality due to ventilator-associated pneumonia or colonization with Pseudomonas or Acinetobacter species: assessment by quantitative culture of samples obtained by a protected specimen brush. Clin Infect Dis 1996; 23: 538–542.

    Article  PubMed  CAS  Google Scholar 

  31. Kollef MH, Silver P, Murphy DM, Trovillion E: The effect of late-onset ventilator-associated pneumonia determining patient mortality. Chest 1995; 108: 1655–1662.

    Article  PubMed  CAS  Google Scholar 

  32. Rello J, Ausina V, Ricart M, Castella J, Prats G: Impact of previous antimicrobial therapy on the etiology and outcome of ventilator-associated pneumonia. Chest 1993; 104: 1230–1235.

    Article  PubMed  CAS  Google Scholar 

  33. Fagon JY, Chastre J, Domart Y, et al: Nosocomial pneumonia in patients receiving continuous mechanical ventilation. Prospective analysis of 52 episodes with use of a protected specimen brush and quantitative culture techniques. Am Rev Respir Dis 1989; 139: 877–884.

    Article  PubMed  CAS  Google Scholar 

  34. Rodriguez de Castro F, Sole Violan J, Lafarga Capuz B, Caminero Luna J, Gonzalez Rodriguez B, Manzano Alonso JL: Reliability of the bronchoscopic protected specimen brush in the diagnosis of pneumonia in mechanically ventilated patients. Crit Care Med 1991; 19: 171–175.

    Article  PubMed  CAS  Google Scholar 

  35. Fink MP, Snydman DR, Niederman MS, et al: Treatment of severe pneumonia in hospitalized patients: Results of a multicenter, randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem/cilastatin. Antimicrob Agents Chemother 1994; 38: 547–557.

    Article  PubMed  CAS  Google Scholar 

  36. Brun-Buisson C, Sollet JP, Schweich H, Briere S, Petit C: Treatment of ventilator-associated pneumonia with piperacillin-tazobactam amikacin versus cetazidime/amikacin: a multicenter, randomized controlled trial. Clin Infect Dis 1998; 26: 346–354.

    Article  PubMed  CAS  Google Scholar 

  37. Schentag JJ, Birmingham MC, Paladino JA, et al: In nosocomial pneumonia, optimizing antibiotics other than aminoglycosides is a more important determinant of successful clinical outcome, and a better means of avoiding resistance. Semin Respir Infect 1997; 12: 278–293.

    PubMed  CAS  Google Scholar 

  38. The EORTC International Antimicrobial Therapy Cooperative Group: Ceftazidime combined with a short or long course of amikacin for empirical therapy of Gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 1987; 317: 1692–1698.

    Article  Google Scholar 

  39. A’Court CH, Garrard CS, Crook D, et al: Microbiological lung surveillance in mechanically ventilated patients, using non-directed bronchial lavage and quantitative culture. Quart J Med 1993; 86: 635–648.

    Article  PubMed  Google Scholar 

  40. Montravers P, Fagon JY, Chastre J, et al: Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147: 38–44.

    Article  PubMed  CAS  Google Scholar 

  41. Souweine B, Veber B, Bedos JP, et al: Diagnostic accuracy of protected specimen brush and bronchoalveolar lavage and nosocomial pneumonia: impact of previous antimicrobial treatment. Crit Care Med 1998; 26(2): 236–244.

    Article  PubMed  CAS  Google Scholar 

  42. Dunn M, Wunderink R: Ventilator-associated pneumonia caused by Pseudomonas infection. Clin Chest Med 1995; 16: 95–109.

    PubMed  CAS  Google Scholar 

  43. Rello J, Ausina V, Ricart M, et al: Risk factors for infection by Pseudomonas aeruginosa in patients with ventilator-associated pneumonia. Intensive Care Med 1994; 20: 193–198.

    Article  PubMed  CAS  Google Scholar 

  44. Trouillet N, Samore MH, Carmeli Y: Imipenem-resistant Pseudomonas aeruginosa: Risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25: 1094–1098.

    Article  Google Scholar 

  45. Sanders CC, Sanders WE: Type I -lactamases of gram-negative bacteria: interactions with -lactam antibiotics. J Infect Dis 1986; 154: 792–800.

    Article  PubMed  CAS  Google Scholar 

  46. Hancock REW: Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998; 27(suppl 1): S93–S99

    Article  PubMed  CAS  Google Scholar 

  47. Silver DR, Cohen IL, Weinberg PF: Recurrent Pseudomonas aeruginosa pneumonia in an intensive care unit. Chest 1992; 101: 194–198.

    Article  PubMed  CAS  Google Scholar 

  48. Cometta A, Baumgartner JD, Lew D, et al: Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrobial Agents and Chemotherapy 1994; 38: 1309–1313.

    Article  PubMed  CAS  Google Scholar 

  49. Brown RB, Kruse JA, Counts GW, et al: Double-blind study of endotracheal tobramycin in the treatment of gram-negative bacterial pneumonia. Antimicrob Agents Chemother 1990; 34: 269–272.

    Article  PubMed  CAS  Google Scholar 

  50. Rello J, Quintana E, Ausina V, Puzo C, Net A, Prats G: Risk factors for Staphylococcus aureus nosocomial pneumonia in critically ill patients. Am Rev Respir Dis 1990; 142: 1320–1324.

    Article  PubMed  CAS  Google Scholar 

  51. Leeper KV, Jennings SG, Jones CB, Wunderink RG: Outcome of ventilator-associated pneumonia due to methicillin-resistant staphylococcus aureus. Chest 2000; 138S(Abstract)

    Google Scholar 

  52. Rouby JJ, De Lassale EM, Poete P, et al: Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis 1992; 148: 1059–1066.

    Article  Google Scholar 

  53. Fagon J-Y, Patrick H, Haas DW, et al: treatment of gram-positive nosocomial pneumonia: Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med 2000; 161: 753–762.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Department, Methodist Le Bonheur Healthcare Foundation, University of Tennessee, Memphis, USA

    Richard G. Wunderink MD (Director, Clinical Associate Professor of Medicine)

Authors
  1. Richard G. Wunderink MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Methodist Health Care, Memphis, TN, USA

    Richard G. Wunderink M.D. (Director of Clinical Research) (Director of Clinical Research)

  2. Critical Care Department, Hospital Universitari Joan XXIII, Carrer Dr. Mallafre Guasch, 4, Tarragona, E-43007, Spain

    Jordi Rello M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Wunderink, R.G. (2001). Treatment of Ventilator-Associated Pneumonia. In: Wunderink, R.G., Rello, J. (eds) Ventilator-Associated Pneumonia. Perspectives on Critical Care Infectious Diseases, vol 4. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0789-5_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0789-5_7

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5240-2

  • Online ISBN: 978-1-4615-0789-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation